All sponsors

Iovance Biotherapeutics, Inc. $IOVA

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-31
RECRUITING6
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO40%

Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Iovance Biotherapeutics, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
IOV-4001
NCT05361174
P1/2RecruitingUnresectable Melanoma; Metastatic Melanoma532027-09 (+27 mo)
Lifileucel
NCT07288203
P2Active, not recruitingMelanoma (Skin Cancer); Unresectable Melanoma242027-12
Lifileucel plus Pembrolizumab
NCT05727904
P3RecruitingMetastatic Melanoma; Unresectable Melanoma6702028-03-01
Lifileucel
NCT06481592
P2RecruitingEndometrial Cancer602028-05
LN-145
NCT04614103
P2RecruitingMetastatic Non Small Cell Lung Cancer1702030-12 (+96 mo)
IOV-3001
NCT06940739
P1/2RecruitingUnresectable Melanoma; Metastatic Melanoma422032-06
'SARATOGA'
NCT07741877
P2RecruitingSarcoma; Soft Tissue Sarcoma (STS)802033-09-01
IOV-5001
NCT07743723
P1/2Not yet recruitingAdvanced Solid Tumors; Non-Small Cell Lung Cancer1062034-03